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Abstract
A clinical Klebsiella pneumoniae isolate carrying the extended-
spectrum b-lactamase gene variants blaSHV-40, blaTEM-116 and
blaGES-7 was recovered. Cefoxitin and ceftazidime activity was
most affected by the presence of these genes and an additional
resistance to trimethoprim-sulphamethoxazole was observed.
The blaGES-7 gene was found to be inserted into a class 1 integ-
ron. These results show the emergence of novel blaTEM and
blaSHV genes in Brazil. Moreover, the presence of class 1 integ-
rons suggests a great potential for dissemination of blaGES genes
into diverse nosocomial pathogens. Indeed, the blaGES-7 gene
was originally discovered in Enterobacter cloacae in Greece and,
to our knowledge, has not been reported elsewhere.
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In South America, rates of extended-spectrum b-lactamase
(ESBL) production in members of the Enterobacteriaceae are
among the highest in the world [1,2]. SHV-derived enzymes
were the ﬁrst ESBLs to be reported in Chile and Argentina
[3,4]. Surprisingly, TEM-derived ESBLs have been described
only recently [5,6], whereas CTX-M-type enzymes are ende-
mic and widely dominant in this region [7]. More recently,
PER-2 and GES-type ESBLs have emerged. Curiously, PER-2
has only been found in South America so far, in isolates from
Argentina, Bolivia and Uruguay [6,8,9], whereas GES-1 and
GES-5 have been sporadically observed in Pseudomonas aeru-
ginosa isolates from Argentina and Brazil [10–12].
In the present study, we report on a single clinical isolate
of Klebsiella pneumoniae carrying the novel ESBL gene variants
blaSHV-40, blaTEM-116 and blaGES-7 in Brazil. In October 2004, a
clinical isolate of K. pneumoniae (strain FSP232/05) was
recovered from a urine sample of an 80-year-old woman
with a catheter-related urinary tract infection who stayed for
2 months in the intensive care unit of a secondary university
hospital in Sa˜o Paulo, Brazil. Initially, the bacterial species and
the antimicrobial susceptibility proﬁle were determined using
a Vitek system (BioMe´rieux, Hazlewood, MO, USA). MICs
were subsequently determined using Etest strips (AB Biodisk,
Solna, Sweden). ESBL production was conﬁrmed using the
combination disk method (Oxoid, Cambridge, UK) and an
Etest ESBL strip. DNA ampliﬁcation by PCR was carried out
using primers speciﬁc for blaTEM, blaSHV, blaCTX-M and blaGES
genes.
The isolate was conﬁrmed as K. pneumoniae by ampliﬁcation
and sequencing of the 16S rRNA gene. The strain was suscep-
tible to imipenem (MIC < 4 mg/L), cefepime (MIC = 0.75 mg/
L), aztreonam (MIC = 3 mg/L), cefotaxime (MIC = 3 mg/L),
amikacin (MIC = 16 mg/L) and ciproﬂoxacin (MIC = 0.125 mg/
L), and it was resistant to cefoxitin (MIC = 64 mg/L), ceftazi-
dime (MIC > 256 mg/L) and trimethoprim-sulphamethoxaz-
ole. The ESBL production was ascertained by a positive
combination disk test, and by a reduction in the MIC of cefo-
taxime in the presence of clavulanate, from 3 to 0.19 mg/L,
using the Etest ESBL strip. PCR screening revealed the
presence of blaSHV, blaTEM and blaGES genes. Nucleotide
sequencing showed 100% sequence identity with blaSHV-40,
blaTEM-116 and blaGES-7, respectively (GenBank accession
numbers EU870433, EU870432 and EF219164). The presence
of blaGES-7 in class 1 integrons was investigated by PCR using:
(i) a forward primer for the conserved sequence of class
1 integrons (5¢-CCGTAGAAGAACAGC-3¢) with the reverse
primer for blaGES-7 and (ii) a forward primer for blaGES genes
with a reverse primer for the conserved sequence of class
1 integrons (5¢-GTTGCGATTACTTCG-3¢). As a result, the
blaGES-7 gene was found to be inserted into a class 1 integron.
Plasmid DNA was isolated using the Wizard Plasmid Miniprep
kit (Promega, Madison, WI, USA). Electrophoresis revealed
the presence of two plasmids, with estimated molecular sizes
of 6 and 23 kb, respectively. However, transformation and
conjugation experiments using Escherichia coli DH5a and
JM109 as recipients were unsuccessful.
Subsequent to the ﬁrst ESBL being identiﬁed in Germany
in 1983 [2], it was soon understood that single or multiple
amino acid substitutions in the classical SHV or TEM
enzymes could alter their spectrum of activity, enhancing
their hydrolyzing ability. Novel ESBL variants arose and,
currently, there are more than 300 enzymes described
worldwide, most of them belonging to the TEM, SHV, OXA
and CTX-M families (http://www.lahey.org/studies/) [1,2].
In Brazilian hospitals, the frequency of ESBL-producing
K. pneumoniae has been higher than that observed in many
European and US hospitals, accounting for approximately
50% of K. pneumoniae isolates recovered from intensive care
units [1], although the molecular characteristics of these
ESBLs have been poorly described. Regarding SHV- and
TEM-derived ESBL genes, only blaSHV-4, blaSHV-5 and blaSHV-27
have been reported, and no blaTEM gene variants have been
characterized so far [13–15].
In the present study, we characterized a single clinical
isolate of K. pneumoniae carrying the novel ESBL gene vari-
ants blaSHV-40, blaTEM-116 and blaGES-7. The blaSHV-40 gene was
identiﬁed, for the ﬁrst time in Canada in 2004, in a clinical
isolate of K. pneumoniae [16]. SHV-40 contains the Leu35Gln
change that has been found in the non-ESBL SHV-11, as well
as an Ala243Gly change that has been found only in SHV-35
[16]. On the other hand, blaTEM-116 was described for the
ﬁrst time in Korea, in a clinical isolate of E. coli [17], and it
has not been previously identiﬁed in K. pneumoniae. TEM-116
has amino acid replacements at positions 84 and 184, which
have not been observed in other TEM-type b-lactamases.
Regarding GES-like enzymes, the ESBL GES-1 was described
for the ﬁrst time in 1998 in a K. pneumoniae isolate from
French Guiana. Subsequently, nine GES variant enzymes have
been reported from diverse geographical locations [18,19].
The presence of blaTEM-116, blaSHV-40 and blaGES-7 genes in
the isolate analyzed here (now labelled strain FSP232/05) led
to an ESBL phenotype, with cefoxitin and ceftazidime activity
being mostly affected by b-lactamase production.
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Indeed, SHV-40 and GES-7-producing strains have been
characterized as being resistant to ceftazidime (CAZ) and
cefoxitin, and susceptible to cefotaxime (CTX), ceftriaxone,
aztreonam (ATM), cefepime, imipenem and meropenem
[16,18]. However, it has been reported that TEM-116 can
confer resistance to CAZ, CTX and ATM [17]. In this
regard, b-lactamases sometimes cause obvious resistance;
often, however, these enzymes reduce susceptibility without
causing resistance according to current breakpoints. One
and the same enzyme may cause different resistance pheno-
types, depending on the bacterial host and the test condi-
tions. In the case of ESBLs of the TEM and SHV families, the
expanded spectrum is accompanied by a loss of intrinsic
hydrolytic activity, which can be compensated for by an
increase in gene dosage or by the presence of a promoter
with increased activity [20].
In conclusion, the results obtained in the present study
suggest that continuous mutation has led to the emergence
of novel blaTEM and blaSHV ESBL gene variants in Brazil. On
the other hand, the presence of class 1 integrons suggests
that resistance associated with GES production can contrib-
ute to the dissemination of these emerging genes into other
nosocomial pathogens. Indeed, the blaGES-7 gene was originally
discovered in Enterobacter cloacae in Greece and, to our
knowledge, has not been reported elsewhere.
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